Oral Version Hedges Bet
I.V. Chemo Payouts Staying Put, Poniard Poises for Big-time Profits
By Randy Osborne
Monday, August 10, 2009
The trim-down tactics this spring by Poniard Pharmaceuticals Inc. to pump more thrust behind the Phase III SPEAR trial put most of the company's oomph behind its "pipeline-in-a-drug" candidate picoplatin, and easily could lead to an acquisition after data roll out by the end of this year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.